CN114939153B - 一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用 - Google Patents
一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用 Download PDFInfo
- Publication number
- CN114939153B CN114939153B CN202210500853.6A CN202210500853A CN114939153B CN 114939153 B CN114939153 B CN 114939153B CN 202210500853 A CN202210500853 A CN 202210500853A CN 114939153 B CN114939153 B CN 114939153B
- Authority
- CN
- China
- Prior art keywords
- adenylate
- yeast peptide
- parts
- composition
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 80
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 79
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 title claims abstract description 66
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 title claims abstract description 59
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 title claims abstract description 59
- FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 62
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 60
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims abstract description 51
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 40
- 108010024636 Glutathione Proteins 0.000 claims abstract description 31
- 229960003180 glutathione Drugs 0.000 claims abstract description 31
- 235000012754 curcumin Nutrition 0.000 claims abstract description 30
- 229940109262 curcumin Drugs 0.000 claims abstract description 30
- 239000004148 curcumin Substances 0.000 claims abstract description 30
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 30
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 26
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 26
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 26
- 229940016667 resveratrol Drugs 0.000 claims abstract description 26
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 24
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 24
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 24
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 20
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 20
- 210000003056 antler Anatomy 0.000 claims abstract description 20
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000005875 quercetin Nutrition 0.000 claims abstract description 20
- 229960001285 quercetin Drugs 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 230000032683 aging Effects 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 16
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 12
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 12
- 244000269722 Thea sinensis Species 0.000 claims abstract 5
- 239000000843 powder Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- DJJCXFVJDGTHFX-XVFCMESISA-L uridine 5'-monophosphate(2-) Chemical compound O1[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-L 0.000 claims description 9
- 230000002000 scavenging effect Effects 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000036541 health Effects 0.000 abstract description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 30
- 241001122767 Theaceae Species 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 239000000047 product Substances 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 230000002292 Radical scavenging effect Effects 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 6
- 235000013928 guanylic acid Nutrition 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- -1 5' -adenylate compound Chemical class 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 108050002485 Sirtuin Proteins 0.000 description 2
- 102000011990 Sirtuin Human genes 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 235000011990 fisetin Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HEILIGJNYTWOHU-UHFFFAOYSA-N ethanol 2-hydroxybenzoic acid Chemical compound CCO.OC(=O)C1=CC=CC=C1O HEILIGJNYTWOHU-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用,属于医药保健技术领域。所述组合物由5’‑尿苷酸、5’‑腺苷酸、酵母肽和功能活性成分按照一定比例调配制成,所述功能活性成分为鹿茸提取物、吡咯喹啉醌(PQQ)、谷胱甘肽、姜黄素、茶多酚、槲皮素、白藜芦醇、α‑硫辛酸、α‑戊酮二酸、非瑟酮中的一种或者几种。所述含有尿苷酸、腺苷酸和酵母肽的组合物具有延缓机体衰老、恢复年轻态等作用,使用后可起到延缓、改善、防止衰老的功效。
Description
技术领域
本发明属于医药保健技术领域,具体涉及一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用。
背景技术
衰老作为生命历程里必经的阶段一直伴随着人类文明的发展,进入21世纪,人们对于衰老进行了更加深度的研究,人们对于衰老的认知也逐渐变化,目前凡是有利于人体健康的,提高生活质量的,都可定义为延缓衰老。延缓衰老的主要方式为非药物与药物两个方面,其中非药物的方法为坚持科学的生活规律,保持良好的生活习惯。而药物的方法分类就比较多,其中大多数是服用保健类药品或食品,其作用效果也是最显著的。
目前市面上的抗衰老产品为了达到很好的抗衰老效果使用了抗氧化性强的工业成分、短时见效快,但是长时间使用对人体危害极大;有的抗衰产品添加维生素类抗氧化剂,但是这类产品稳定性差。
核苷酸是核糖核酸及脱氧核糖核酸的基本组成单位,是体内合成核酸的前身物。核苷酸随着核酸分布于生物体内各器官、组织、细胞的核及胞质中,并作为核酸的组成成分参与生物的遗传、发育、生长等基本生命活动。
发明内容
本发明的目的在于提供一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用。本发明经过长期研究发现,不同的核苷酸有不同的功能,搭配添加其他功能性成分后可以高效清除体内自由基,延缓细胞老化,恢复年轻态。本发明为核苷酸类营养品在提高人体健康水平、人们生活质量的应用方面提供了一种新思路。
本发明为实现上述目的,通过以下技术方案实现:
一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物,所述组合物包括5’-尿苷酸、5’-腺苷酸、酵母肽和功能活性成分,所述功能活性成分包括鹿茸提取物、吡咯喹啉醌(PQQ)、谷胱甘肽、姜黄素、茶多酚、槲皮素、白藜芦醇、α-硫辛酸、α-戊酮二酸、非瑟酮中的一种或者两种以上。
进一步地,上述技术方案中,所述组合物中5’-尿苷酸、5’-腺苷酸、酵母肽和功能性成分包括如下重量份数组分:5’-腺苷酸0.3-1.2份、5’-尿苷酸0.3-1.2份、酵母肽0.05-1.5份、功能活性成分0.88-7.35份。
进一步地,上述技术方案中,所述功能活性成分包括如下重量份数组分:鹿茸提取物1-2份、吡咯喹啉醌0.01-0.05份、谷胱甘肽0.25-1份、姜黄素0.12-0.6份、茶多酚0.5-1份、槲皮素0.5-1.25份、白藜芦醇0.02-0.1份、α-硫辛酸0.01-0.1份、α-戊酮二酸0.3-1份、非瑟酮0.05-0.25份中的一种或者两种以上。
进一步地,上述技术方案中,所述组合物包括如下重量份数的组分:5’-腺苷酸0.6份、5’-尿苷酸0.6份、酵母肽0.25份、鹿茸提取物2份、吡咯喹啉醌0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份、白藜芦醇0.051份;或者所述组合物包括如下重量份数的组分:5’-腺苷酸0.6份、5’-尿苷酸0.6份、酵母肽0.25份、鹿茸提取物2份、α-硫辛酸0.05份、α-戊酮二酸0.3份、吡咯喹啉醌0.02份、姜黄素0.19份、非瑟酮0.1份、谷胱甘肽0.25份、白藜芦醇0.051份。
进一步地,上述技术方案中,所述组合物包括如下重量份数的组分:5’-尿苷酸0.3份、5’-腺苷酸0.3份、酵母肽0.17份、吡咯喹啉醌0.01份、谷胱甘肽0.25份、姜黄素0.12份、茶多酚0.5份;或者5’-尿苷酸0.6份、5’-腺苷酸0.6份、酵母肽0.25份、吡咯喹啉醌0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份、白藜芦醇0.051份;或5’-尿苷酸0.3份、5’-腺苷酸0.3份、酵母肽0.17份、非瑟酮0.05份、吡咯喹啉醌0.01份、谷胱甘肽0.25份、姜黄素0.12份、茶多酚0.5份;或5’-腺苷酸0.6份、5’-尿苷酸0.6份、酵母肽0.25份、α-硫辛酸0.05份、α-戊酮二酸0.3份、吡咯喹啉醌0.02份、姜黄素0.19份、非瑟酮0.1份、谷胱甘肽0.25份、白藜芦醇0.051份。
进一步地,上述技术方案中,所述鹿茸提取物来源于新鲜鹿茸。
进一步地,上述技术方案中,所述组合物的成品状态包括粉剂、颗粒剂、片剂、丸剂、口服液、胶囊。
本发明还提供了上述含有尿苷酸、腺苷酸和酵母肽的组合物在制备抗衰老药品、保健品或营养食品中的应用。
进一步地,上述技术方案中,所述药品、保健品或营养食品具有清除体内自由基、抗氧化、对损伤细胞良好的保护和修复、延缓机体衰老、恢复年轻态的作用。
本发明相对于现有技术具有的有益效果如下:
本发明提供了包含5’-尿苷酸、5’-腺苷酸、酵母肽及其他功能活性成分的组合物及应用,所述功能活性成分包括鹿茸提取物、吡咯喹啉醌(PQQ)、谷胱甘肽、姜黄素、茶多酚、槲皮素、白藜芦醇、α-硫辛酸、α-戊酮二酸、非瑟酮中的一种或者两种以上。研究发现5’-尿苷酸、5’-腺苷酸可提升胃肠道益生菌存活率进而改善肠道环境,促进大分子物质分解,加速多种活性成分的的吸收与转运。因此,推测并经实验结果验证,核苷酸、酵母肽和其他活性成分配伍,可加强组合物延缓衰老和抗衰老的功效。
附图说明
图1为本发明所述含有尿苷酸、腺苷酸和酵母肽的组合物对D-半乳糖小鼠血清中谷胱甘肽过氧化物酶(GSH-PX)含量的影响。图中:#表示与模型组比较,差异有统计学意义(P<0.05);*表示与空白组比较,差异有统计学意义(P<0.05)。
图2为本发明所述含有尿苷酸、腺苷酸和酵母肽的组合物对D-半乳糖小鼠血清中超氧化物歧化酶(SOD)含量的影响。图中:#表示与模型组比较,差异有统计学意义(P<0.05);*表示与空白组比较,差异有统计学意义(P<0.05)。
图3为本发明所述含有尿苷酸、腺苷酸和酵母肽的组合物对D-半乳糖小鼠血清中丙二醛(MDA)含量的影响。图中:#表示与模型组比较,差异有统计学意义(P<0.05)。
图4为本发明所述含有尿苷酸、腺苷酸和酵母肽的组合物对衰老小鼠寿命的影响。
具体实施方式
下面结合具体实施例对本发明的作进一步解释说明,这些实施例应被理解为仅是举例说明,而非以任何方式限制本发明的范围。下述实施例中,如无特殊说明,所使用的实验方法均为常规方法,所用材料、试剂等均可从生物或化学公司购买。
实施例1
按照重量配比为5’-尿苷酸0.6份、5’-腺苷酸0.6份、酵母肽0.25份、鹿茸提取物2份、PQQ 0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份、白藜芦醇0.051份在洁净区称取原料,用混合机混合均匀,得到粉剂。成品按质量标准的规定取样进行各项指标的检验,检验合格后保存备用。
实施例2
按照重量配比为5’-尿苷酸0.6份、5’-腺苷酸0.6份、酵母肽0.25份、鹿茸提取物2份、α-硫辛酸0.05份、α-戊酮二酸0.3份、吡咯喹啉醌0.02份、姜黄素0.19份、非瑟酮0.1份、谷胱甘肽0.25份、白藜芦醇0.051份在洁净区称取原料,用混合机混合均匀,得到粉剂。成品按质量标准的规定取样进行各项指标的检验,检验合格后保存备用。
实施例3
按照重量配比为5’-尿苷酸0.3份、5’-腺苷酸0.3份、酵母肽0.17份、PQQ 0.01份、谷胱甘肽0.25份、姜黄素0.12份、茶多酚0.5份在洁净区称取原料,用混合机混合均匀,得到粉剂。成品按质量标准的规定取样进行各项指标的检验,检验合格后保存备用。
实施例4
按照重量配比为5’-尿苷酸0.6份、5’-腺苷酸0.6份、酵母肽0.25份、PQQ 0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份、白藜芦醇0.051份在洁净区称取原料,用混合机混合均匀,得到粉剂。成品按质量标准的规定取样进行各项指标的检验,检验合格后保存备用。
实施例5
按照重量配比为5’-尿苷酸0.3份、5’-腺苷酸0.3份、酵母肽0.17份、非瑟酮0.05份、PQQ 0.01份、谷胱甘肽0.25份、姜黄素0.12份、茶多酚0.5份在洁净区称取原料,用混合机混合均匀,得到粉剂。成品按质量标准的规定取样进行各项指标的检验,检验合格后保存备用。
实施例6
按照重量配比为5’-腺苷酸0.6份、5’-尿苷酸0.6份、酵母肽0.25份、α-硫辛酸0.05份、α-戊酮二酸0.3份、吡咯喹啉醌0.02份、姜黄素0.19份、非瑟酮0.1份、谷胱甘肽0.25份、白藜芦醇0.051份在洁净区称取原料,用混合机混合均匀,得到粉剂。成品按质量标准的规定取样进行各项指标的检验,检验合格后保存备用。
实施例7含有尿苷酸、腺苷酸和酵母肽的组合物的抗氧化性能
将实施例1制备的粉剂,准备称重后溶解于去离子水和乙醇的混合溶液中(体积比为1:1),制得浓度为1mg/mL的母液,进行DPPH自由基清除率的测定和OH-自由基清除率的测定。
1.DPPH自由基清除率的测定:
将母液分别稀释100,50,25,10,1倍制备成浓度为10μg/mL,20μg/mL,40μg/mL,100μg/mL,500μg/mL的梯度稀释液。
分别取上述浓度150μL样品和150μL浓度为60mg/L的DPPH溶液(无水乙醇稀释)置于96孔板中,混合均匀,30℃避光保存,30min后使用酶标仪测量519nm下吸光度值。DPPH自由基清除率公式如下:
式中,A空白为150μL去离子水乙醇溶液和150μL DPPH溶液的吸光度,A样品为150μL样品和150μL DPPH溶液的吸光度;IC50为DPPH自由基清除率达到50%时样品的浓度。
2.OH-自由基清除率的测定:
(1)将母液分别稀释100,50,25,10,1倍制备成浓度为10μg/mL,20μg/mL,40μg/mL,100μg/mL,500μg/mL的梯度稀释液。
(2)分别取上述浓度50μL样品和50μL浓度为6mmol/L的FeSO4溶液,加入50μL浓度为6mmol/L的乙醇-水杨酸溶液,置于96孔板中,混合均匀后,加入50μL浓度为6mmol/L的H2O2溶液,混合均匀。
(3)在37℃条件下反应30min后将96孔板放入酶标仪测量510nm下吸光度值(A样品)。OH-自由基清除率公式如下:
式中,A空白为用DMSO代替体系中的样品的吸光度,A样品为50μL样品的吸光度。IC50为OH-自由基清除率达到50%时样品的浓度。
实施例2-6制备的粉剂样品参照上述方法检测DPPH自由基清除率和OH-自由基清除率。
对照组1:单组份5’-尿苷酸。
对照组2:单组份5’-腺苷酸。
对照组3:单组份酵母肽。
对照组4:5’-尿苷酸0.6份和5’-腺苷酸0.6份复配的组合物。
对照组5:5’-尿苷酸0.6份、5’-腺苷酸0.6份、酵母肽0.25份复配的组合物。
对照组6:5’-鸟苷酸0.6份、5’-胞苷酸0.6份、酵母肽0.25份复配的组合物。
对照组7:酵母肽0.25份、鹿茸提取物2份、PQQ 0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份、白藜芦醇0.051份。
对照组8:酵母肽0.25份、PQQ 0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份、白藜芦醇0.051份。
实验数据以均值±标准偏差表示,实验结果如表1所示。
表1含有尿苷酸、腺苷酸和酵母肽的组合物的抗氧化性能
结果表明,与对照组1-8相比,实施例1-6的含有尿苷酸、腺苷酸和酵母肽的组合物均具有较高的抗氧化性能,表现出更强的清楚DPPH自由基和OH-自由基的能力,尿苷酸和腺苷酸与酵母肽和功能活性成分复配后抗氧化性能呈现显著增强的效果,实施例1-6的组合物能够更有效的清除机体的自由基。
本发明将尿苷酸、腺苷酸、酵母肽和功能活性成分复配制备的组合物相较于单组份尿苷酸、单组份腺苷酸、单组份酵母肽、仅为酵母肽复配功能活性成分、两种核苷酸复配(5’-尿苷酸和5’-腺苷酸按重量比1:1复配)、两种核苷酸复配酵母肽(5’-尿苷酸:5’-腺苷酸:酵母肽按重量比0.6:0.6:0.25复配)或5’-鸟苷酸、5’-胞苷酸和酵母肽复配的混合物均具有显著的清除自由基的能力,清除DPPH自由基以及清除OH-自由基的能力得到明显提升。同时可以增强生物体中抗氧化酶的活性,达到延缓衰老的目的。尿苷酸和腺苷酸与酵母肽起到协同作用,增强了清除自由基的能力,复配功能活性成分后,效果得到进一步提升。
实施例8含有尿苷酸、腺苷酸和酵母肽的组合物体外延缓衰老性能
以人脐静脉内皮细胞、PC-12细胞(大鼠肾上腺嗜铬细胞瘤细胞)为模型,采用H2O2造模,对实施例1-6的组合物进行细胞内ROS水平的评价。
对照组1:单组份5’-尿苷酸。
对照组2:单组份5’-腺苷酸。
对照组3:单组份酵母肽。
对照组:4:5’-尿苷酸0.6份和5’-腺苷酸0.6份复配的组合物。
对照组5:5’-尿苷酸0.6份、5’-腺苷酸0.6份、酵母肽0.25份复配的组合物。
对照组6:5’-鸟苷酸0.6份、5’-胞苷酸0.6份、酵母肽0.25份复配的组合物。
对照组7:酵母肽0.25份、鹿茸提取物2份、PQQ 0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份、白藜芦醇0.051份。
对照组8:酵母肽0.25份、PQQ 0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份、白藜芦醇0.051份。
H2O2作用细胞后产生大量ROS,攻击细胞膜、蛋白质及核酸,导致细胞损伤。将对数生长期的细胞消化成单细胞悬液,调节细胞浓度为105个/mL,接种于96孔细胞培养板,每孔100μL,每组6个平行孔。接种24小时后,细胞贴壁生长,弃上清,加入终浓度200μmol/L的H2O2的培养基培养4h,然后替换为终浓度分别为50μg/mL的实施例1-6的组合物培养液继续培养24小时。实验同时设置不加H2O2的空白对照和只加H2O2的模型组,用活性氧检测试剂盒进行细胞内活性氧的状况评价:每孔加入10μmol/L的DCFH-DA母液(DMSO溶解),终浓度为1μmol/L。继续培养2小时后,弃去上清,每孔加PBS 100μL洗涤2次,离心后使用200μL的PBS重悬细胞,使用荧光酶标仪于激发波长485nm,发射波长为525nm条件下测定各孔荧光强度,计算细胞的活性氧含量。实验数据以均值±标准偏差表示,实验结果如表2所示。
表2人脐静脉内皮细胞和PC-12细胞内的活性氧含量
人脐静脉内皮细胞荧光强度 | PC-12细胞荧光强度 | |
模型组 | 20492±239 | 17783±148 |
实施例1 | 2208±169 | 2056±202 |
实施例2 | 2573±148 | 2399±193 |
实施例3 | 3049±137 | 2908±183 |
实施例4 | 2790±160 | 2561±134 |
实施例5 | 3353±146 | 3149±181 |
实施例6 | 2938±107 | 2708±148 |
对照组1 | 14755±124 | 13498±174 |
对照组2 | 14872±168 | 13874±140 |
对照组3 | 16331±195 | 16004±108 |
对照组4 | 13072±164 | 12986±199 |
对照组5 | 3572±190 | 3551±170 |
对照组6 | 13915±192 | 13080±167 |
对照组7 | 13109±134 | 13043±159 |
对照组8 | 13865±107 | 13180±147 |
上述结果表明,和模型组以及对照组1-8的组合物相比,实施例1-6的组合物能够显著降低模型细胞内的活性氧,实施例1-6的组合物对氧化损伤的细胞具有良好的保护和修复作用。
本发明将尿苷酸、腺苷酸、酵母肽和功能活性成分复配制备的组合物相较于单组份尿苷酸、单组份腺苷酸、单组份酵母肽、仅为酵母肽复配功能活性成分、两种核苷酸复配(5’-尿苷酸和5’-腺苷酸按重量比1:1复配)、两种核苷酸复配酵母肽(5’-尿苷酸:5’-腺苷酸:酵母肽按重量比0.6:0.6:0.25复配)或5’-鸟苷酸、5’-胞苷酸和酵母肽复配的混合物均具有显著的降低H2O2损伤的细胞内活性氧含量的能力,有助于使衰老氧化损伤的细胞得以修复,降低细胞内活性氧含量的能力得到显著提升。尿苷酸和腺苷酸与酵母肽起到协同作用,增强了降低细胞内活性氧的能力,复配功能活性成分后,效果得到进一步提升。
实施例9含有尿苷酸、腺苷酸和酵母肽的组合物对D-半乳糖诱导小鼠的作用
5周大的BALB/c小鼠,饲养一周后,其中20只用50mg/kg的D-半乳糖腹腔注射30天,30天后,以10只为一组。
实验组:分别按照实施例1-6的组合物灌胃共28天,并同时腹腔注射D-半乳糖。
对照组1:灌胃与组合物相同体积的5’-尿苷酸共28天,并同时腹腔注射D-半乳糖。
对照组2:灌胃与组合物相同体积的5’-腺苷酸共28天,并同时腹腔注射D-半乳糖。
对照组3:灌胃与组合物相同体积的酵母肽共28天,并同时腹腔注射D-半乳糖。
对照组4:灌胃与组合物相同体积的5’-尿苷酸0.6份和5’-腺苷酸0.6份复配的组合物共28天,并同时腹腔注射D-半乳糖。
对照组5:灌胃与组合物体积相同的5’-尿苷酸0.6份、5’-腺苷酸0.6份、酵母肽0.25份复配的组合物共28天,并同时腹腔注射D-半乳糖。
对照组6:灌胃与组合物相同体积的5’-鸟苷酸0.6份、5’-胞苷酸0.6份、酵母肽0.25份复配的组合物共28天,并同时腹腔注射D-半乳糖。
对照组7:灌胃与组合物相同体积的酵母肽0.25份、鹿茸提取物2份、PQQ0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份、白藜芦醇0.051份复配的组合物共28天,并同时腹腔注射D-半乳糖。
对照组8:灌胃与组合物相同体积的酵母肽0.25份、PQQ 0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份、白藜芦醇0.051份复配的组合物共28天,并同时腹腔注射D-半乳糖。
模型组:灌胃与组合物相同体积的PBS缓冲液。
空白组:腹腔注射与D-半乳糖同等剂量的生理盐水,30天后灌胃与组合物相同体积的PBS缓冲液,同时持续腹腔注射,共28天。
灌胃结束的第二天,眼眶采血后,用于后续实验。
实验结果如图1-图3所示,血清中氧化酶SOD和GSH-PX的含量均增加,丙二醛减少,说明本发明所述组合物能缓解D-半乳糖对小鼠的氧化损伤。与对照组1-8相比,实施例1-6所述的组合物均表现出更强的抗氧化损伤的能力,尿苷酸和腺苷酸与酵母肽协同作用,复配功能活性成分后,效果得到进一步提升。
实施例10尿苷酸、腺苷酸和酵母肽的组合物对自然衰老小鼠衰老的延缓作用
8周大的BALB/c小鼠,随机分为两组,每组10只,实验组:分别按照实施例1-6的组合物灌胃至小鼠衰老自然死亡。空白组:灌胃同等提及的生理盐水至小鼠衰老自然死亡。对照组1:灌胃与组合物相同体积的5’-尿苷酸至小鼠衰老自然死亡。对照组2:灌胃与组合物相同体积的5’-腺苷酸至小鼠衰老自然死亡。对照组3:灌胃与组合物相同体积的酵母肽至小鼠衰老自然死亡。对照组4:灌胃与组合物相同体积的5’-尿苷酸0.6份和5’-腺苷酸0.6份复配的组合物至小鼠衰老自然死亡。对照组5:灌胃与组合物体积相同的5’-尿苷酸0.6份、5’-腺苷酸0.6份、酵母肽0.25份复配的组合物至小鼠衰老自然死亡。对照组6:灌胃与组合物相同体积的5’-鸟苷酸0.6份、5’-胞苷酸0.6份、酵母肽0.25份复配的组合物至小鼠衰老自然死亡。对照组7:灌胃与组合物相同体积的酵母肽0.25份、鹿茸提取物2份、PQQ 0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份、白藜芦醇0.051份复配的组合物至小鼠衰老自然死亡。对照组8:灌胃与组合物相同体积的酵母肽0.25份、PQQ 0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份、白藜芦醇0.051份复配的组合物至小鼠衰老自然死亡。
分别统计各组小鼠的生长寿命,结果如图4所示,本发明所述的含有尿苷酸、腺苷酸和酵母肽的组合物可以有效延缓小鼠自然衰老。
对于任何熟悉本领域的技术人员而言,在不脱离本发明技术方案范围情况下,都可利用上述揭示的技术内容对本发明技术方案作出许多可能的变动和修饰,或修改为等同变化的等效实施例。因此,凡是未脱离本发明技术方案的内容,依据本发明的技术实质对以上实施例所做的任何简单修改、等同变化及修饰,均应仍属于本发明技术方案保护的范围内。
Claims (7)
1.一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物,其特征在于,所述组合物的组成为5’-尿苷酸、5’-腺苷酸、酵母肽和功能活性成分,所述功能活性成分选自鹿茸提取物、吡咯喹啉醌、谷胱甘肽、姜黄素、茶多酚、槲皮素、白藜芦醇、α-硫辛酸、α-戊酮二酸和非瑟酮中的一种或者两种以上;
所述组合物中5’-尿苷酸、5’-腺苷酸、酵母肽和功能性成分的重量份数组分如下:5’-腺苷酸0.6-1.2份、5’-尿苷酸0.6-1.2份、酵母肽0.05-1.5份、功能活性成分0.88-7.35份;
所述功能活性成分的重量份数组分如下:鹿茸提取物1-2份、吡咯喹啉醌0.01-0.05份、谷胱甘肽0.25-1份、姜黄素0.12-0.6份、茶多酚0.5-1份、槲皮素0.5-1.25份、白藜芦醇0.02-0.1份、α-硫辛酸0.01-0.1份、α-戊酮二酸0.3-1份、非瑟酮0.05-0.25份。
2.根据权利要求1所述的组合物,其特征在于,所述组合物由如下重量份数的组分组成:5’-腺苷酸0.6份、5’-尿苷酸0.6份、酵母肽0.25份、鹿茸提取物2份、吡咯喹啉醌 0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份和白藜芦醇0.051份;或者所述组合物由如下重量份数的组分组成:5’-腺苷酸0.6份、5’-尿苷酸0.6份、酵母肽0.25份、鹿茸提取物2份、α-硫辛酸0.05份、α-戊酮二酸0.3份、吡咯喹啉醌 0.02份、姜黄素0.19份、非瑟酮0.1份、谷胱甘肽 0.25份和白藜芦醇0.051份。
3.根据权利要求1所述的组合物,其特征在于,所述组合物由如下重量份数的组分组成:5’-尿苷酸 0.6份、5’-腺苷酸 0.6份、酵母肽 0.25份、吡咯喹啉醌0.02份、谷胱甘肽0.25份、姜黄素0.19份、茶多酚0.5份、槲皮素0.5份和白藜芦醇0.051份;或5’-腺苷酸0.6份、5’-尿苷酸0.6份、酵母肽0.25份、α-硫辛酸0.05份、α-戊酮二酸0.3份、吡咯喹啉醌 0.02份、姜黄素0.19份、非瑟酮0.1份、谷胱甘肽0.25份和白藜芦醇0.051份。
4.根据权利要求1所述的组合物,其特征在于,所述鹿茸提取物来源于新鲜鹿茸。
5.根据权利要求1-4中任一项所述的组合物,其特征在于,所述组合物的成品状态为粉剂、颗粒剂、片剂、丸剂、口服液或胶囊。
6.权利要求1-5中任一项所述的含有尿苷酸、腺苷酸和酵母肽的组合物在制备抗衰老药品中的应用。
7.根据权利要求6所述的应用,其特征在于,所述药品具有清除体内自由基、抗氧化、对损伤细胞良好的保护和修复、延缓机体衰老、恢复年轻态的作用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210500853.6A CN114939153B (zh) | 2022-05-09 | 2022-05-09 | 一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用 |
PCT/CN2023/091947 WO2023216951A1 (zh) | 2022-05-09 | 2023-05-04 | 一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210500853.6A CN114939153B (zh) | 2022-05-09 | 2022-05-09 | 一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114939153A CN114939153A (zh) | 2022-08-26 |
CN114939153B true CN114939153B (zh) | 2023-04-28 |
Family
ID=82906351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210500853.6A Active CN114939153B (zh) | 2022-05-09 | 2022-05-09 | 一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114939153B (zh) |
WO (1) | WO2023216951A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114939153B (zh) * | 2022-05-09 | 2023-04-28 | 大连双迪科技股份有限公司 | 一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1646078A (zh) * | 2002-04-09 | 2005-07-27 | 大塚制药株式会社 | 细胞增殖用组合物 |
CN113615837A (zh) * | 2021-07-30 | 2021-11-09 | 珍奥集团股份有限公司 | 一种延缓衰老的核苷酸益生菌胶囊 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002101846A (ja) * | 2000-09-28 | 2002-04-09 | Kohjin Co Ltd | 5’−ヌクレオチド高含有酵母エキスの製造方法 |
US20040101934A1 (en) * | 2001-02-27 | 2004-05-27 | Choe Yun Seok | Peptide derived from yeast having activities as anti-tsress, anti-fatigue and brain neurotrophic factor and relaxing premenstrual syndrome and menstrual pain, and preparing process thereof |
CN107557417A (zh) * | 2016-06-30 | 2018-01-09 | 安琪酵母股份有限公司 | 酵母多肽及其制备方法和应用 |
CN110251527B (zh) * | 2019-06-06 | 2021-06-25 | 泓博元生命科技(深圳)有限公司 | 含烟酰胺单核苷酸的组合物在抗衰老药品/保健品的应用 |
TWI834988B (zh) * | 2020-08-25 | 2024-03-11 | 大江生醫股份有限公司 | 富含菸醯胺單核苷酸的酵母粉的製備方法、酵母粉及其改善肌膚狀況、頭髮護理、抗發炎、心血管保健、抗氧化、抗老化及/或改善身體疲憊程度之用途 |
JP2022054483A (ja) * | 2020-09-28 | 2022-04-07 | 曙光ライフテック株式会社 | Nmn含有抗酸化組成物及びその調製方法 |
CN113577092B (zh) * | 2021-07-30 | 2022-07-01 | 陈玉松 | 一种延缓衰老的含核苷酸的组合物及其制备方法和应用 |
CN114272356A (zh) * | 2022-01-12 | 2022-04-05 | 孟庆雄 | 一种延缓衰老药物组合物的配方及其制作方式 |
CN114939153B (zh) * | 2022-05-09 | 2023-04-28 | 大连双迪科技股份有限公司 | 一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用 |
CN114931625A (zh) * | 2022-05-09 | 2022-08-23 | 大连双迪科技股份有限公司 | 尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用 |
-
2022
- 2022-05-09 CN CN202210500853.6A patent/CN114939153B/zh active Active
-
2023
- 2023-05-04 WO PCT/CN2023/091947 patent/WO2023216951A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1646078A (zh) * | 2002-04-09 | 2005-07-27 | 大塚制药株式会社 | 细胞增殖用组合物 |
CN113615837A (zh) * | 2021-07-30 | 2021-11-09 | 珍奥集团股份有限公司 | 一种延缓衰老的核苷酸益生菌胶囊 |
Non-Patent Citations (1)
Title |
---|
Jaume Folch等.Experimental Models for Aging and their Potential for Novel Drug Discovery.Curr Neuropharmacol .2018,第16卷(第10期),第1466-1483页. * |
Also Published As
Publication number | Publication date |
---|---|
CN114939153A (zh) | 2022-08-26 |
WO2023216951A1 (zh) | 2023-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106616979A (zh) | 一种姜黄果蔬酵素的制备方法及应用 | |
Jing et al. | Antioxidant activity, antitumor effect, and antiaging property of proanthocyanidins extracted from Kunlun Chrysanthemum flowers | |
CN114939153B (zh) | 一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用 | |
WO2023216952A1 (zh) | 尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用 | |
Yapar et al. | Protective effect of kombucha mushroom (KM) tea on phenol-induced cytotoxicity in albino mice | |
CN107997155B (zh) | 一种组合物、其应用和抗氧化、改善记忆力的产品 | |
CN110897968A (zh) | 一种蒜氨酸保湿水及其制备方法 | |
Peeri et al. | Effect of aqueous extract of saffron and aerobic training on hepatic non enzymatic antioxidant levels in streptozotocin-diabetic rats | |
EP4166154A1 (en) | Magnetized elderberry ferment for preventing osteoporosis and improving immunity and use for antioxidation by the same | |
CN113876610B (zh) | 一种能够增强细胞能量并提高皮肤抵抗力的组合物及其制备方法与应用 | |
KR20160121632A (ko) | 효모 발효 허브 복합체을 이용하여 항산화 효과가 우수하고 저자극인 추출물의 제조 방법 | |
KR20160121633A (ko) | 황칠액 발효대사체를 포함하는 항노화 기능성 조성물 | |
TWI699208B (zh) | 蔬莓果發酵物的製備方法及其用途 | |
CN114948813A (zh) | 一种抗糖化、抗衰老天然产物组合物及其制备方法和在口服美容产品中的应用 | |
CN114948789A (zh) | 一种具有高效抗蓝光功效的sod组合物及其制备方法 | |
JP2009007268A (ja) | キサントンの吸収性を向上させたサラシア加工物及びその製造方法 | |
TW202102133A (zh) | 用於製備一發酵產物的方法及其所製得的發酵產物暨其應用 | |
US20240180815A1 (en) | Methods for resisting skin aging by using kiwiberry extract | |
JP7455350B2 (ja) | 大気汚染物質によるダメージ抑制剤、化粧料及び飲食品 | |
CN116235948B (zh) | 一种抗糖化组合物及其应用 | |
KR101074649B1 (ko) | 능이버섯 및 마카 추출물을 포함하는 미백 및 항산화용 화장료 조성물 | |
JP2009013103A (ja) | キサントンの吸収性を向上させたマンゴスチン加工物及びその製造方法 | |
CN105496883A (zh) | 一种阴香果提取物在个人护理品中的应用 | |
KR20240094197A (ko) | 효소 및 발효반응 녹용추출물의 제조방법과 그에 의한 효소 및 발효반응 녹용 추출물 | |
TWI538683B (zh) | 黑柄炭角菌菌絲體之製備方法、黑柄炭角菌菌絲體萃取物、其製備方法及其抗氧化組合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40079442 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |